Key Takeaways
- Tarik Mize posted a solid 3.71 ERA and 1.2 fWAR in his first full big‑league season (2021), showing marked improvement in command (BB/9 fell from 4.13 to 2.45).
- He relied increasingly on his four‑seam fastball while cutting back on the splitter and sinker, which helped lower opponents’ hard‑hit contact to 40 % and barrels to 10 %.
- A Tommy John surgery in June 2022 ended his 2022 campaign after only 10 innings and kept him shelved for the entire 2023 season.
- Mize returned in 2024, making 20 starts (22 appearances) with a 4.49 ERA over 102.1 innings, but was hampered early by a right adductor strain and later by a left hamstring injury that landed him on the 60‑day IL.
- In 2025 he earned his first All‑Star selection (as an injury replacement), posting a 5.7 % walk rate and a career‑low 78.1 % contact rate while pitching to a 3.87 ERA across 149 innings.
- Despite the encouraging trends in control and suppression of hard contact, recurring injuries continue to interrupt his durability, leaving his ability to stay healthy and sustain front‑line starter performance an open question for 2026 and beyond.
Tarik Mize’s first full season as a member of the major‑league rotation came in 2021, and it offered a glimpse of the pitcher he could become. Over 30 starts he logged 150.1 innings, finishing with a 3.71 ERA and a respectable 1.2 fWAR. While his strikeout rate of 7.1 per nine innings fell short of the coveted one‑per‑inning mark, the real story was his command. Mize cut his walks per nine innings from a troubling 4.13 in 2020 to a much more manageable 2.45, a reduction that directly contributed to his improved effectiveness.
The improvements were not limited to walk rates. Mize also posted the lowest opponents’ hard‑hit percentage of his career at 40 %, with barrels constituting just 10 % of batted balls. To achieve this, he altered his pitch mix: he leaned heavily on his four‑seam fastball, dialed back the usage of his splitter, and virtually abandoned the sinker. The shift paid off, as the four‑seamer generated more swing‑and‑miss while inducing weaker contact.
Unfortunately, the innings surge came at a steep physical cost. After logging only 10 innings in 2022, Mize underwent Tommy John surgery in June of that year. The procedure forced him to miss the remainder of the 2022 campaign and the entirety of the 2023 season, raising concerns about whether the mechanical adjustments he had made could survive the rigors of a full workload after such a major elbow reconstruction.
Mize returned to the mound in 2024, appearing in 22 games and starting 20 of them. He accumulated 102.1 innings with a 4.49 ERA, a step back from his 2021 numbers but a noteworthy achievement given the layoff. The season was, however, marred by early‑year setbacks: a right adductor strain during spring training limited his early work, and a left hamstring strain later in the year landed him on the 60‑day injured list in July, sidelining him until late August. These interruptions prevented him from building the continuity needed to solidify his role in the rotation.
The 2025 season marked a turning point. Mize earned his first All‑Star nod—though as an injury replacement for Red Sox left‑hander Garrett Crochet, the selection underscored the recognition of his performance. He posted a 5.7 % walk rate, continuing the downward trend in free passes that began in 2021, and achieved a career‑low 78.1 % contact rate. Over 149 innings he compiled a 3.87 ERA, showing that when healthy he could suppress hard contact and keep opposing offenses at bay.
Yet the pattern of promise interrupted by injury persisted. Even as his peripherals improved, Mize faced another setback that landed him on the injured list later in the year, reminding observers that durability remains his biggest obstacle. The question heading into 2026 is whether the gains in command, pitch selection, and ability to limit hard‑hit balls can be sustained over a full season without further interruptions. If he can stay on the mound, the data suggest he has the tools to evolve into a reliable front‑of‑the‑line starter; if the injury cycle continues, his value may remain confined to sporadic, high‑impact appearances rather than a steady rotation anchor.
In summary, Mize’s trajectory has been defined by a promising leap in control and effectiveness, a major elbow surgery that cost him two seasons, a tentative comeback hampered by soft‑tissue strains, and a resurgent 2025 that hinted at his true potential. The next chapter will hinge on his ability to stay healthy long enough to let those improvements translate into consistent, elite‑level performance.